NIS to examine the effectiveness and safety of durvalumab and olaparib in patients with endometrial cancer (DUOLife)

Trial Identifier: D9311R00001
Sponsor: AstraZeneca
Collaborator:
North-Eastern German Society of Gynecological Oncology (NOGGO e.V.)
Start Date: May 2025
Primary Completion Date: September 2028
Study Completion Date: September 2028
Condition: Endometriosis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Berlin, Germany
Germany Bielefeld, Germany
Germany Borna, Germany
Germany Bottrop, Germany
Germany Brandenburg an der Havel, Germany
Germany Dessau, Germany
Germany Ebersberg, Germany
Germany Guetersloh, Germany
Germany Landshut, Germany
Germany Leipzig, Germany
Germany Lueneburg, Germany
Germany Mainz, Germany
Germany Plauen, Germany
Germany Unna, Germany
Germany Worms, Germany